EdiGene raises $62M to expand gene editing technologies

By The Science Advisory Board staff writers

April 21, 2021 -- Biotech company EdiGene has raised $62 million in financing to expand its genome editing technologies and to accelerate drug discovery and therapies.

This funding adds to the approximately $67 million the company raised in October 2020. Proceeds will be used to advance the company's pipeline into clinics and to scale up global business operations.

This year, the company's lead candidate, an investigational CRISPR/Cas9 gene editing therapy for patients with transfusion dependent beta-thalassemia, was the first hematopoietic stem cell therapy investigational new drug application approval in China. The company is also preparing to initiate a trial for other drug candidates, including allogeneic chimeric antigen receptor (CAR) T-cell therapy and in vivo therapies based on an RNA base editing technology called leveraging endogenous ADAR for programmable editing of RNA (LEAPER).

The series B plus financing round was led by Loyal Valley Capital.

EdiGene, Immunochina to develop CAR-T therapy
EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.

Copyright © 2021 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter